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Abstract  
Objectives: Health economic models are developed as part of the health technology 
assessment process in order to determine whether health interventions represent good 
value for money.  These models are often used to directly inform health care decision-
making and policy. The information needs for the model require the use of other types of 
information beyond clinical effectiveness evidence in order to populate the model 
parameters.  The purpose of this research study was to explore issues concerned with the 
identification and use of information for the development of such models. 
Methods: Three focus groups were held in February 2011 at the University of Sheffield with 
13 UK HTA experts.  Attendees included health economic modellers, information specialists 
and systematic reviewers. Qualitative framework analysis was used to analyse the focus 
group data. 
Results: Six key themes, with related sub themes, were identified. The themes were model 
development, searching issues, reviewing issues, communication, knowledge and 
experience and reporting issues.  There was considerable overlap between themes. 
Conclusions: Key issues raised by the respondents included the need for effective 
communication and teamwork throughout the model development process, the importance 
of using clinical experts as well as the need for transparent reporting of methods and 
decisions. 
 
Keywords: qualitative-research, model-parameters; cost-effectiveness-modelling; health-
technology-assessment; evidence-based-decision-making 
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Introduction 
The development of a health economic model typically forms part of the health technology 
assessment (HTA) process together with the development of a systematic review of the 
clinical effectiveness of the intervention being assessed.  Health economic models require 
information in addition to clinical efficacy data and this includes evidence relating to relevant 
comparators, health utilities, resource use and costs, among others. Sources of evidence 
may include: randomised controlled trials (RCTs), observational evidence and other clinical 
studies, disease registers, elicitation of expert clinical judgement, existing cost-effectiveness 
models, routine data sources and health valuation studies.  The way in which these 
information needs are identified and used can have a fundamental impact on the results of 
the model (1) and therefore on health care decisions and resulting policies.  There is often a 
lack of transparency associated with how information needs are met in the development of 
cost effectiveness models.  Drummond et al (2) found that much of the relevant data for 
estimating quality adjusted life years (QALYs) were not contained in the systematic review 
for the HTA, and that the chosen method for summarising the clinical data can inhibit the 
assessment of economic benefit.   
 
Although some of the issues around the identification and reviewing of evidence for models 
have been discussed previously (1, 3-8) there remains very little formal guidance with 
respect to best practice in this area.  This is an important consideration as it is not possible 
to review all evidence systematically to inform a health economic model and choices need to 
be made in terms of how evidence is synthesised and used.  In their ISPOR-SMDM 
Modelling Good Research Practice Report (9), Briggs et al recommend that analysts should 
conform to the broad principles of evidence‐based medicine and avoid “cherry picking” the 
best single source of evidence.  While there is a need for transparent and reproducible 
methods there are also time and resource constraints which can influence how the model 
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development process operates.  Chilcott et al (10) suggest that a potential source of errors in 
health technology assessment models is the separation of the information gathering, 
reviewing and modelling functions while Drummond et al (2) also suggest that some of the 
problems associated with model development could be reduced if evidence requirements 
were discussed at an early stage. 
 
Kaltenthaler, Tappenden and Paisley (11, 12) have investigated issues relating to the 
conceptualisation of cost effectiveness models and the identification and review of evidence 
to inform models.  Shared and explicit decision-making and transparent reporting of the 
choices and judgements that underpin model development were seen as being of key 
importance in the development of acceptable methods that take into account the specific 
requirements of the model development process.  This research has gone some way 
forward in highlighting the key issues and offering suggestions for improving the model 
development process and the way in which it is reported. These are important issues that 
need to be considered by those involved in health technology assessments, including both 
researchers and decision makers.   
 
The aim of this paper is to presents the findings from a series of focus groups held with UK 
HTA experts to explore some of the issues and concerns associated with the identification 
and review of evidence used in the development of cost effectiveness models. These 
findings are part of the evidence used to inform a recent NICE Technical Support Document 
(TSD) (13) and the issues specifically related to the selection and review of evidence are 
described in more detail elsewhere (12).  
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Materials and methods 
Three focus groups were held as part of a workshop with 13 HTA experts from UK 
universities in February 2011.  The participants were a purposive sample, chosen to 
represent a variety of specialisms and included seven modellers, one health economist, one 
statistician, two information specialists and two systematic reviewers.  Ethical approval for 
the focus groups was obtained from the University of Sheffield Research Ethics Committee.  
The focus groups were facilitator led (EK) and were recorded using digital media with the 
recordings transcribed verbatim.  Standard qualitative research methods were used to 
conduct the focus groups and analyse the data (14).  Framework analysis (14) was used to 
develop a thematic framework and the qualitative data were classified and organised into 
key themes and subthemes. The initial step was familiarisation with the transcribed data.  
Data were then coded and the conceptual framework was developed.  Coding was checked 
by a second reviewer.  Some of the themes were pre-identified and some were emergent.  
The topic guide for the focus groups is shown in Table 1.  The discussions were open and 
participants were invited to discuss other points they felt were relevant but had not been 
included in the guide. 
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Table 1. Focus group topic guide 
Session topic Aim of the session and related questions 
Model development  To identify key steps in model development and implementation (How 
does your “final” model structure arise? How do you know which 
parameters are relevant? How iterative is the process?).  
Time constraints  To identify ways we might deal with the issue of time constraints in 
reviewing for model parameters (What compromises are acceptable 
to make?). 
Sufficient evidence  To explore how we determine when there is sufficient evidence for 
model parameters and model development. (What is your 
interpretation of sufficient evidence?). 
Communication and 
team work 
To identify what constitutes good practice with regard to team work 
and communication. (What defines good communication and team 
work in this context?). 
Problem structuring  To recommend good practice with regard to problem structuring (How 
do you decide what should be included in a model and what should 
be excluded?). 
Identification of 
evidence 
To provide guidance on key issues of evidence identification (non-
standard information, rapid searching, comprehensiveness and 
sensitivity (Do we need to provide guidance on how to access non-
standard information?  How do we handle issues related to 
comprehensiveness and sensitivity? What advice can we offer with 
respect to rapid searching?). 
Reviewing methods To identify practical guidance for reviewing model parameters (How 
do we appraise for both quality and relevance? How does the 
process of inclusion/exclusion differ in the context of modelling? With 
rapid review methods what compromises are we willing to make?). 
Recommendations 
for reporting  
To provide practical recommendations on reporting of methods and 
decisions in reviewing for model parameters (How do we report 
decision making and judgements? What needs to be reported to 
allow judgement of the credibility of the model?).  
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Results 
From the focus group transcripts the following six themes were identified: model 
development; searching issues; reviewing issues; communication; knowledge and 
experience and reporting issues.  There was overlap between the themes as many of the 
issues raised were interrelated.  The themes and related subthemes are shown in Table 2. 
 
Table 2. Focus group themes and related subthemes 
Theme Related subthemes 
Model development • decision making  
• planning   
• use of existing models  
• conceptual models  
Searching issues • multiple information needs  
• sources of evidence 
Reviewing issues • selection and prioritisation of data  
• reviewing methods 
• minimising bias 
• hierarchies of evidence 
• study selection 
• assessment of evidence  
• evidence synthesis  
Communication • whole team communication  
• use of clinical experts  
• communication with information specialists 
Knowledge and 
experience 
• expertise  
• previous experience 
Reporting issues • transparency  
• language  
• accuracy vs. credibility 
 
 
9 
 
Theme 1 Model development  
It was highlighted during the focus groups that a large number of decisions and judgements 
are made by modellers during the process of model development especially on aspects of 
relevance and appropriateness to the decision problem. 
“So if you set up five criteria and then you end up judging what you choose on the 
basis of six criteria, only two of which were of the five you started out with, then I 
think it tells you something about how much judgement is required in the process..” 
 
However, the participants expressed concerns regarding the difference in judgements made 
by different modellers to represent the same part of reality.  Hence the participants would 
feel more comfortable if the judgement to a particular decision problem did not rest solely 
with the individual developing the model but rather as a joint task between modellers, 
decision-makers, health professionals and other stakeholders who impact upon or are 
impacted upon by the decision problem under consideration.  Failure to reflect conflicting 
views between alternative stakeholders may lead to the development of models which 
represent a contextually naïve and uninformed basis for decision-making. 
“There is also an issue of whose judgement it is - is it down to the modeller to make 
that judgement or should it be in conjunction with other people in the team or a 
clinical expert? I don’t feel comfortable about the modeller making all these 
judgements.”   
Planning was regarded as a key element for model development.  This could be in the form 
of a protocol or project plans that clearly state the project timelines, methodology for the 
model, information needs and key roles and responsibilities for all team members.  Having 
the evidence requirements set prior to model implementation may allow the whole team to 
identify potentially useful information and may also help to keep track of changes made 
during the process. 
 “I think that it would be useful for us to map out a list of things that you might 
consider … it may be useful to map out pathways in this particular way or problem 
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structuring methods may have some role in identifying what should be included in a 
model and you could even suggest how that should be done.”  
“Knowing in advance the key pieces of information you’re likely to need so that 
whoever is doing your title and abstract screening at the very beginning has enough 
codes for flagging things that may be of interest to the modellers.”  
 
The use of existing cost effectiveness models was discussed and the modellers’ at the focus 
groups indicated that the main reason they used existing models to inform model 
development was to critique them from various angles so that they can avoid repeating the 
same mistakes and in turn produce a better model. 
“I don’t review models for their results, I don’t review them to find things that I like – I 
review them to find things to avoid”   
 
Whilst the use of existing models was considered to be potentially useful, it was suggested 
that they should be used with caution and should not be relied upon without considerable 
scrutiny, as the appropriateness or credibility of an existing model may be questionable or 
there may be a gap between the decision problem that the model was developed to address 
and the current decision problem under consideration. 
 “Well, you have to be a bit careful with that, don’t you?  Sometimes you trace it back 
and you find somebody just thought that number up about twenty years ago, and 
everyone’s used it and they’ve all done that since.”  
 
Conceptual model development was an area where there was variability between 
participants concerning their approaches.  Respondents discussed the use of several 
approaches including documenting proposed model structures, developing mock-up models 
in Microsoft Excel, developing sketches of potential structures, and producing written 
interpretations of the evidence.  However the participants did all agree that having a draft 
model or conceptual model would help to develop a common understanding of the evidence 
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requirements amongst those involved in the model development.  This would help to ensure 
that health professionals understood how the model would capture the impact of the 
interventions under consideration on costs and health outcomes, that the proposed model 
was clinically relevant and met the needs of the decision-maker, and provide an explicit 
platform for considering and debating alternative model structures and other model 
development decisions prior to implementation. 
“You’ve got to sort of get a feel of what the model is doing, not just looking at a whole 
lot of numbers on the spread sheet.  So that’s why I’m a big believer in a back-of-an-
envelope version of the model, which, .. forces you to really understand what’s going 
on in the model.”  
 “start with a conceptual model … you can start with where you think the model 
should be, and then when you reach the point where you haven’t got the data to put 
in the model and you have to simplify it.”  
 
Furthermore, the interviewees expressed that where possible, alternative model 
development choices should be tested to assess their impact upon the model results.  
“I guess my view of structural uncertainty is it’s where you’re equivocal about whether 
one set of assumptions is superior to another and it could be an entire 
characterisation of a disease process, which could have a flag which switches on and 
off, but you’d have to have built that model as well. And I think it’s quite closely 
related to how formal the conceptual modelling is in identifying what those 
alternatives could be. I wouldn’t expect someone to build 10 different models, but I’d 
expect them to consider what else they could have done and I’d like to know what 
else they could have done.”  
 
Theme 2 Searching issues 
One common concern raised amongst the interviewees in the focus groups was the need for 
appropriate searching methods to ensure the retrieval of relevant evidence for the model.  
12 
 
As cost effectiveness models have multiple information needs which require different types 
of evidence drawn from a variety of information sources, it was considered difficult to capture 
the information needs in a single search query.  Therefore, exhaustive search methods such 
as those used in systematic reviews may not be feasible. 
“…it’s relatively easy to find cost studies, it’s relatively easy to find RCTs, it’s not so 
easy to find adverse events because they’re hidden, they’re not described in the 
records, so I think maybe hints about how difficult it is to search for something like 
this in Medline ..might be helpful.”  
 
During the interviews, respondents discussed the difficulties in finding evidence and the 
different approaches used for seeking information, including formal Medline and other 
database searching, contacting experts in the field, searching registries and administrative or 
routine data sources, snowballing references, following leads, semantic technology, text 
databases and focused searching.  However, the majority of the information retrieval 
processes are not explicit.  
“In terms of parameters, we frequently have parameters that are only ever reported 
incidentally and are not included in any keywords, any titles or anything, things like 
unusual or irregular adverse events, for example, that turn up in a table, over a wide 
range of trials and non-trial (evidence), - how do you find them? I don’t know any 
systematic way that could do that. It’s pot luck really, you suddenly come across one 
and then a few more, and they may be different indications even and it’s difficult to 
find a realistic range.”  
“… I’m sure that some of the things I’ve had to resort to to obtain particular estimates 
much more resemble investigative journalism than having anything to do with what 
I’m trained to do”  
“…picking up the phone to lots of people to find out (what) is there .. an individual 
patient dataset for this class of people? .. it’s not all about reviewing, it’s not all about 
bibliographic searches.”  
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The need for guidance and advice was expressed regarding factors that impact on the way 
evidence is identified e.g. what search techniques might be used to maximise the rate of 
return of potentially relevant evidence and to ensure appropriate steps have been taken to 
make the process systematic, reproducible and transparent. 
“It’s any information whatsoever, and the identification of evidence is any information 
seeking process, which includes searching on Medline formally or phoning people up 
or having a group of clinicians who advise your project, you draw information from all 
of them and you use that information as evidence to support or justify or make 
decisions about the model to give it credibility. And as soon as you start to say, well 
yes there is a difference and we just need guidance on searching, it suddenly 
excludes a lot of information seeking processes that are absolutely knitted in to the 
model development process and.... includes clinicians, they have a role in modelling 
.. it’s that idea of credibility I think, that they give such a lot to”  
 
Theme 3 Reviewing issues 
Reviewing issues identified by the participants included: selection and prioritisation of data, 
methods for reviewing, the importance of minimising bias, the use of hierarchies of evidence, 
issues around study selection, assessment of evidence and evidence synthesis.  These are 
covered in considerably more detail elsewhere (12). 
 
The processes of selecting and prioritising evidence used to inform parameter estimates 
were considered to be important.  It was suggested that additional attention should be given 
to the reporting of parameters which are deemed to be more important to the model or to 
instances in which the preferred decision regarding the choice of evidence is equivocal.  The 
participants felt that it was important to prioritise parameters and focus reviewing resources 
on those most likely to impact on model outputs, bearing in mind that the importance of 
parameters is subject to change during the course of the modelling process.   
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Due to the time and resource constraints within the HTA process it was felt that rapid review 
methods might be necessary to identify and select evidence.  As the use of rapid review 
methods risk missing relevant information it was considered essential that methods were 
reported transparently, including the potential limitations of the chosen methods.  
 
A variety of potential biases may be introduced through the process of rapidly reviewing 
evidence to inform model parameters estimates.  Bias may also be introduced through the 
purposive selection of evidence to create more or less favourable results.  One suggested 
option to reduce such bias was to ensure and to demonstrate that more than one member of 
the team was involved with making decisions where choices about parameter values and 
distributions need to be made.   
“…when somebody is making a decision it isn’t just one person it’s a team, because 
… most of the methods within systematic reviewing are double checking what 
everybody has done.  So maybe … for the modellers to use the systematic reviewers 
and a range of clinical advisors to make sure that no one person makes the decision 
about these without consulting.” 
There is a wide range of types of evidence used to populate models and hierarchies of 
evidence sources, as suggested by Coyle et al (15), were felt to be useful as a means of 
judging the quality of individual parameter estimates and aid the study selection process.  In 
order to incorporate the quality of individual studies into the selection process, the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) (16) system was 
suggested as potentially providing a framework for rating the quality of evidence from all 
potential sources of all data components that may be used to populate model parameter. 
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“…using the GRADE system… fairly early as soon as you had your conceptual 
model you might take that to your decision-makers and say which are the critical and 
important clinical outcomes which can extend to all the different parameters as well.” 
 
With regard to study selection and assessment of evidence, it was suggested that relevance 
or applicability could be assessed first in order to speed up the evidence selection process. 
“Normally you go through a full gamut of analysing threats to internal validity first but 
actually if you look at applicability or relevance first, in a time constrained scenario, 
often that fatally rules out a huge bunch of stuff that you don’t need to look at.”  
 
The participants felt that after appraising studies for relevance, quality, should be assessed 
preferably using standardised quality assessment tools.  In this context, quality assessment 
may be difficult due to the absence of standardised methods for all types of information used 
to populate the model.  Also, some studies may be poorly reported.  Establishing quality 
assessment criteria a priori was a recommended option.   
 
In many situations, the issue of synthesis was not considered relevant due to study 
heterogeneity and the case that often only one or two values are appropriate for use in 
populating a model parameter. However, where there are more than one or two potentially 
relevant studies the participants stressed the importance of appropriate synthesis methods.     
 
Theme 4 Communication  
Focus group participants agreed that in order to have a credible and robust model effective 
communication across the whole project team was crucial.  This might include modellers, 
clinical experts, decision-makers, information specialists, systematic reviewers of 
effectiveness studies and other researchers.  The group agreed that all parties involved 
should have a common understanding of the model development process which could be 
achieved by recruiting clinical experts quite early on in the process and involving them in the 
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development of the conceptual model, writing  protocols, highlighting  evidence needs, and 
having regular meetings with the whole team, presenting and discussing the model.  These 
meetings should use non-technical language easily understood by clinical experts and other 
team members.  Also considered important was the sharing of internal draft reports.  
“…always having clinical experts, and not just one who is local and face-to-face, but 
a panel who are available for sort of correspondence by e-mail, very early.  You 
recruit them early and involve them in the model development process, which again 
will also be a fairly whole-team endeavour initially, so that the people who are doing 
the systematic review of effectiveness studies will be party to most of those 
conversations about the conceptual modelling of what the model structure might 
eventually look like.”  
 
Engaging with experts and other researchers can serve as a face validity check to ensure 
that important information has not been missed, that the most appropriate parameter 
estimates are used and the opportunity for errors is reduced. 
“this is another reason why it’s important to have, as well as clinical experts, .. other 
people who are researchers or have worked in the area, so at least after you’ve 
made some of these choices, then you can do .. reality checks and say, .. is there 
anything we’ve missed, are there any other recent or grey literature studies that 
might provide an alternative estimate …..?”  
 
An issue raised during the focus groups was the lack of communication and understanding 
between modellers and information specialists.  This inadvertently led to the development of 
ineffective search strategies.  It was felt important that modellers engage with the information 
specialist and keep them updated with the process of model development and information 
needs so that an effective and focused search strategy can be developed. 
 “the ..ability to go back to the information scientists and say this is more specifically 
what I’m looking for, but likewise also once the preliminary modelling results come 
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back, that that should feedback as well to say we don’t need to do this search 
anymore because the parameter that we thought it was going to inform is not going 
to affect the way this particular model works ...”  
 
Theme 5 Knowledge and experience  
Expert opinion was considered to be crucial in developing the model structure especially that 
of clinical experts, as this was felt to help to develop an understanding of the decision 
problem. 
“When we are presented with a new disease area, often the first time …. You are 
missing things all the way down the line.  If you had.....somebody else’s expertise in 
the modelling field to draw on, you could make a much better job of it.”  
 
In addition, opinions of clinicians and a wider group of people who are involved in caring for 
patients are essential, as they can help provide parameter estimates or identify alternative 
sources of evidence (including unpublished literature).  Hence, this information forms the 
cornerstone of a model’s contextual relevance.  
“….but also expert opinion.  It just seemed to be one of the main adverse events of 
the use of cochlear implants in children that the clinical community had very high on 
going concerns about, so I think we had early feedback that the model could or 
should try to include it, even though our early pilot model had shown it was negative.”  
 
Furthermore clinical experts and other researchers can serve as a reality check to ensure 
that important information has not been missed and that the values used are appropriate. 
“one of our … clinical experts... pointed out that viral resistance was not included in 
our model.  And we’d reviewed every single model of prophylaxis – none of those 
included it, and we’d reviewed the clinical evidence base, and that wasn’t there ..and 
it completely changed the results.”   
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The modeller’s previous knowledge and experience of the disease area was also considered 
to be extremely important, particularly in a time and resource constrained scenario. 
 “If you’ve been working in that field, and built up a network in it, then you are a long 
way ahead, and you have what you need.”  
“…you’ve got some ideas about what’s going to be potentially reliable information 
that could also inform the search and make the search results a bit briefer.”  
 “I think there’s something else also about the historical, and, perhaps, the individual 
experience of what has tended to drive the results of models.  So I think utility 
weights of key health states would be a key thing that past experience would have 
shown often ends up being one of the most important drivers of results” 
 
Theme 6 Reporting issues 
Transparency was considered to be an important issue by the focus group participants.  It 
was also felt that there often was not enough time to ensure that the methods used were 
reported adequately. 
“I think transparency is one of the big things that is missing, isn’t it? In the whole of 
modelling, anyway, there’s the transparency issue.”   
“...even if you have enough time to do that as an analyst you might not have enough 
time to write it up in a way that would make it more transparent.” 
 
A comprehensive account of every evidence source used in the modelling process was 
considered to be very time consuming and potentially difficult to read.  Suggested 
alternatives included the use of a brief summary table of the main inputs and sources of 
information in the main report with the possibility of more detailed information presented in 
appendices.  
 
As highlighted in Theme 1, model development involves making a large number of decisions 
and judgements.  The participants believed that it was important that these decisions are 
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clearly documented and reported to ensure the credibility of the model.  Key aspects include 
the following: search strategies, selection and justification of studies and model parameters; 
structural assumptions, decisions relating to the prioritisation of key information needs, 
acknowledgment of limitations and potential biases and documentation of any deviations 
from the study protocol. 
“you would want to explain your choice.  You would want to, because that would 
support the credibility, wouldn’t it?”  
“It’s more like the thought process you went through to get there, and what did you, 
you decide not to do, and why did you not go that way, or why did you choose this 
way?”  
“As long as you make the choice explicit …, give an indication where the selection 
came from and what other possibilities there were, that would .. be uncertainty rather 
than bias that if we had chosen this one, this would have happened.”  
 
Several participants believed that the language used in reporting model development and 
results should be clearly understood by health professionals and other individuals involved in 
the process. The model could be represented in both diagrammatic and textual forms using 
non-technical, non-mathematical language. 
“Again the language to describe that sort of thing would have to be very careful 
because I think, the way I would write it, would almost always imply it’s going to be a 
Markov model which may not be the best way of modelling something, so I think 
however it’s expressed, it needs to be more in terms of principles and things to 
consider than anything too prescriptive.”  
 
In terms of model credibility it was emphasised that the modeller needs to cater for the target 
audience and there is a tension between accuracy and credibility. 
“..but you know that the clinical audience … will expect to see that factor, because 
the literature has been going on about it for years, like the risk of meningitis with 
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cochlear implants, …..  It’s important for people to see the Markov state for it, even if 
it’s functionally going to be useless.  So I think we are playing lots of tensions to do 
with meeting the right audience, trading off accuracy versus credibility.”  
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Discussion 
This research highlights some important issues in the identification and review of evidence 
for model parameters as identified by the focus group participants who are all experts in the 
field of health technology assessment.  Six key themes were identified by the participants: 
model development, searching issues, reviewing issues, communication, knowledge and 
experience and reporting issues.  The respondents thought that the model development 
process requires a large number of decisions and judgement and several approaches to 
conceptual modelling were suggested.  The types of information needed and the sources of 
this information were issues felt by the respondents to warrant different approaches to 
searching than those found within the field of systematic reviewing.  Reviewing efforts should 
be focused on those parameters deemed to be more important to the model and 
transparency in the reporting of review methods was considered essential.  Effective 
communication with all members of the modelling team throughout the process was 
considered important.  The use of clinical experts was deemed to be essential and the 
modeller’s and other team members experience in a specific disease area were both thought 
to be useful for development of models.  Transparency was considered crucial in the 
reporting of methods and results and documentation of decisions made throughout the 
process was thought to be important to ensure the model’s credibility.  There was 
considerable overlap between themes. For example, reviewing of previous models was 
suggested as useful for informing searching approaches. 
 
The participants in these focus groups have several years of experience in the field of cost-
effectiveness modelling of health technologies.  The findings from these focus groups helped 
to inform the development of a NICE Technical Support Document providing guidance on 
the identification and review of evidence for cost effectiveness model (13).  This goes some 
way forward in suggesting options for good practice in identifying and reviewing evidence for 
use in cost effectiveness models.  These issues are of interest to all those working in health 
22 
 
technology assessment internationally, including researchers and policy makers as how 
evidence is identified and reviewed for used in cost effectiveness models can have a big 
impact on health technology assessments and subsequent health care policy decisions. 
 
There were some limitations with this research.  Only UK participants were included in the 
focus groups.  Researchers from other countries may have different views.  Only one 
method (focus groups) was used to collect data.  There may have been different results if 
interviews, questionnaires or other qualitative research methods were used.  Only academic 
researchers participated in the focus groups and it would therefore be useful to determine 
the views from industry, health outcomes and research agencies and policy making 
agencies such as NICE in subsequent research.   
 
There are many unanswered questions with respect to how to identify, review and select 
evidence to inform model parameters, hence a number of areas warrant further research.  
There is a need for accepted standards for documentation of decisions and the use of 
sources of evidence such as expert clinical opinion.  There is also a need for the 
development of appropriate search methods and rapid review methods for the identification 
and review of evidence used in cost effectiveness models. 
 
Conclusions 
The findings of this research highlight some of the important issues in the use of evidence in 
cost effectiveness models.  Effective communication and team work throughout the model 
development process was considered important was transparent reporting of decisions 
made throughout the process. These issues are of importance to policy makers and those 
involved in making decisions regarding the use of health technologies.  Consideration of 
these issues helps to make the model development process more transparent and easier to 
understand and thus facilitates health care decision making and health policy development. 
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